Alzheimer's Disease
Alzheimer’s disease is a progressive neurological disorder that causes memory loss and cognitive decline. It is the most common type of dementia, and it is estimated that 6.9 million people 65 years of age and older have Alzheimer’s disease in the United States.
Treatment
TB006 is a humanized monoclonal antibody (mAB) that targets Galectin 3 to reduce toxic neuroinflammation and prevent protein aggregation. Phase 1b/2 trial results showed significant patient improvement and excellent safety data.
Galectin-3 is a protein that plays a significant role in various biological processes including cell adhesion, inflammation, apoptosis and is often a biomarker for various conditions such as Alzheimer’s disease.
Dr. Rose is a Principal Investigator for expanded access with TB006 treatment in adults with Alzheimer’s disease and related dementias.
Frequently Asked Questions
Expanded access provides an opportunity for eligible patients to gain access to an investigational medical treatment when no satisfactory alternative therapy options are available.
- Diagnosis of Alzheimer’s disease
- At least 56 years of age
- Mini Mental Status Exam score of 24 or less
- Failure of at least one other medications for Alzheimer’s disease (i.e. Exelon, Aricept, Namenda)
TB006 is administered intravenously. It is recommended to be given once per year, but preferably once a month for four months and then at intervals determined based on the patient’s individual needs.
TB006 is experimental and is still undergoing clinical trials, but has shown to be effective in slowing and reversing Alzheimer’s disease. In a clinical trial, half of the patients given TB006 for three months had a reversal of symptoms and improved memory and cognition.
Insurance does not cover the cost of TB006. A physical exam and blood work must be done prior to the treatment.
Terrain Health offers a variety of IV therapies many of which may benefit those with AD. These IVs include Cerebrolysin, Curcumin and Resveratrol.